Literature DB >> 15574684

Evidence for pleiotropic signaling at the mouse beta3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate].

Dana S Hutchinson1, Masaaki Sato, Bronwyn A Evans, Arthur Christopoulos, Roger J Summers.   

Abstract

This study examines the action of the beta(3)-adrenoceptor antagonist SR59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanoloxalate] at cloned mouse beta(3)-adrenoceptors expressed in Chinese hamster ovary cells (CHO-K1-beta(3)) or endogenously expressed in 3T3-F442A adipocytes or ileum. SR59230A displayed partial agonist properties compared with the beta(3)-adrenoceptor agonist CL316243 [(R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]-propyl]1,3-benzodioxole-2,2-dicarboxylate] in CHO-K1-beta(3) with the intrinsic activity increasing with the level of receptor expression. Functional affinity values for SR59230A at each level of receptor expression were in agreement with pK(I) values determined by binding. In cytosensor microphysiometer studies, SR59230A was a full agonist for increases in extracellular acidification rates (ECARs) at all levels of receptor expression, and antagonist actions were measurable only in medium- or low-expressing cells. In 3T3-F442A adipocytes, SR59230A antagonized CL316243-mediated increases of cAMP and had no agonist actions. However, in the cytosensor micro-physiometer, SR59230A (acting via beta(3)-adrenoceptors) was an agonist with an intrinsic activity greater than CL316243. In mouse ileum, SR59230A relaxed smooth muscle, although concentration-response curves were biphasic. Relaxant effects were produced by concentrations that did not affect cAMP levels. Differences in tissue responses to SR59230A were not caused by major differences in expression of Galphas. ECAR responses were not affected by pretreatment of cells with pertussis toxin, indicating that signaling did not involve Gi. Therefore, SR59230A displays agonist and antagonist actions at the mouse beta(3)-adrenoceptor. Because SR59230A only antagonized accumulation of cAMP in 3T3-F442A adipocytes yet in the same cells was an agonist for ECAR, cAMP-independent signaling pathways must mediate part of the agonist actions in the microphysiometer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15574684     DOI: 10.1124/jpet.104.076901

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Interaction with caveolin-1 modulates G protein coupling of mouse β3-adrenoceptor.

Authors:  Masaaki Sato; Dana S Hutchinson; Michelle L Halls; Sebastian G B Furness; Tore Bengtsson; Bronwyn A Evans; Roger J Summers
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 2.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

3.  Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor.

Authors:  Edilson Dantas da Silva Junior; Masaaki Sato; Jon Merlin; Natalie Broxton; Dana S Hutchinson; Sabatino Ventura; Bronwyn A Evans; Roger J Summers
Journal:  Br J Pharmacol       Date:  2017-06-10       Impact factor: 8.739

Review 4.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

Review 5.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

6.  Role of β-adrenoceptors in glucose uptake in astrocytes using β-adrenoceptor knockout mice.

Authors:  Stephanie L Catus; Marie E Gibbs; Masaaki Sato; Roger J Summers; Dana S Hutchinson
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

7.  Agonist effects of zinterol at the mouse and human beta(3)-adrenoceptor.

Authors:  Dana S Hutchinson; Ekaterina Chernogubova; Masaaki Sato; Roger J Summers; Tore Bengtsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-07       Impact factor: 3.000

8.  A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.

Authors:  Jillian G Baker
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

Review 9.  The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.

Authors:  Jonathan R S Arch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-09       Impact factor: 3.000

10.  Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.

Authors:  Bertrand Rozec; Thuy Tran Quang; Jacques Noireaud; Chantal Gauthier
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.